Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster ...
Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that its Phase 2b ASPIRE trial ...
As America grapples with a deadly opioid epidemic, there's a desperate need for better, non-addictive painkillers. Using science out of Harvard and $27 million in fresh funding, a health startup just ...
Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced the appointment of Vineet Agarwal, ...
Nocion's $27 million series A will bankroll the company from discovery through proof of concept. (Pixabay) () It’s a familiar story—you need a cavity filled, so the dentist gives you a local ...
The U.K.’s Medicines and Healthcare products Regulatory Agency gave Nocion a speedy approval last month for the phase 1 study of the cough-suppressing treatment. (Pixabay) () Nocion Therapeutics has a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CEO Richard Batycky said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results